Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: bahr o. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U; Neuro-Oncology Group of the German Cancer Society. Glas M, et al. Among authors: bahr o. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub 2011 Jun 27. Ann Neurol. 2011. PMID: 21710625 Clinical Trial.
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. Weller M, et al. Among authors: bahr o. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655102 Free article. Clinical Trial.
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Schaub C, et al. Among authors: bahr o. J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28. J Cancer Res Clin Oncol. 2018. PMID: 29808316 Clinical Trial.
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Kebir S, et al. Among authors: bahr o. J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19. J Neurooncol. 2019. PMID: 31325144 Clinical Trial.
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Weller J, et al. Among authors: bahr o. Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2. Lancet Oncol. 2019. PMID: 31488360 Clinical Trial.
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Weiler M, et al. Among authors: bahr o. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):670-6. doi: 10.1016/j.ijrobp.2009.05.031. Epub 2009 Oct 14. Int J Radiat Oncol Biol Phys. 2010. PMID: 19836157 Free article. Clinical Trial.
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O. Schaub C, et al. Among authors: bahr o. J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193554
73 results